How to Get Rid of Jowls Without Surgery: Filler, Ultherapy, Morpheus8 or Threads?

The changes that produce jowls sit in three different tissues, and each one points to a different treatment.

Volume is the first.

After rapid weight loss, surgeons describe the facial change as volume loss and soft-tissue descent from reduced facial fat, and a 2025 imaging study of 20 patients on GLP-1 drugs (mean weight loss 11 kg) found a median 9% decrease in midface volume — on average, its authors write, 7% of midfacial volume per 10 kg of total weight lost — mainly in the superficial fat pads.

Laxity is the second.

In a 2026 survey of 406 aesthetic clinicians, midface volume loss and face and neck skin laxity were among the changes most linked to GLP-1 weight loss, and the American Academy of Dermatology (AAD) cautions that with a lot of sagging skin, tightening may not help.

Fat is the third: fullness from under-chin fat is its own treated entity — the only area Kybella is approved for.

Which tissue is driving your jowls is not something a checklist can settle — a licensed provider assesses it in person.

The sections below set out what each option is approved or cleared to do.

Filler works on the volume side, and two approvals frame the approach. Juvéderm Voluma XC is approved for cheek augmentation for age-related midface volume loss and for chin augmentation (PMA supplement S047, 12 Jun 2020), and for moderate to severe temple hollowing in adults over 21 (S070, 6 Oct 2023).

On the jawline itself, Juvéderm Volux XC is approved for improving jawline definition in adults over 21 with moderate to severe loss of jawline definition (PMA P110033/S065, 29 Jul 2022), and Radiesse (+) is approved for deep injection to improve moderate to severe loss of jawline contour in adults over 21 (PMA P050052/S129, 1 Sep 2021).

None of those approvals names the jowl.

The FDA approves fillers for specific areas only, and it may not have reviewed use elsewhere — so a filler plan aimed directly at the jowl rather than at the approved cheek, chin, temple or jawline indications is off-label: it is not on any current US label for that product.

The US jawline study of Volux did dose the area: its instructions allowed up to 8.0 mL total (initial plus touch-up, both sides), and participants averaged about 6 mL across up to 9 sites — chin, pre-jowl, post-jowl, marionette lines and jaw angles — which the study's authors say is more than would likely be used in practice.

That is a trial figure, not a dose recommendation.

How the cheek half of this works in practice is the cheek filler guide's subject.

Sculptra for jowls is its own search term, so here is the label position: Sculptra (poly-L-lactic acid) is approved, in immune-competent people, to correct shallow to deep nasolabial fold contour deficiencies and other facial wrinkles (2009) and for fine lines and wrinkles in the cheek region (PMA P030050/S039, 25 Apr 2023) — the jowl is not among those areas.

It also behaves differently: most fillers show results immediately, while Sculptra shows results in 2 to 3 weeks and builds over time.

Filler redness, swelling, tenderness and bruising usually clear within 7 to 14 days, per the AAD.

Duration depends on the material, and the two reference sources disagree enough that we give both.

The AAD's table lists hyaluronic acid at 4 to 12 months, calcium hydroxylapatite at 6 months to 1 year and poly-L-lactic acid at 1 to 3 years; the FDA's filler page gives hyaluronic acid about 6 to 12 months, calcium hydroxylapatite about 18 months and PLLA up to 2 years.

Duration varies by product and area.

In the 2026 survey of 406 aesthetic clinicians about GLP-1 weight loss, hyaluronic acid filler was considered the best treatment for facial concerns for an average of 47% of those patients — a clinician opinion survey with co-authors from Allergan Aesthetics, not trial data and not a jowl-specific finding.

The dermal fillers guide compares the products, and the sculptra guide covers the months-long timeline in depth.

None of the device clearances we read names the jowl — the cleared wording covers the areas around it or stays general. Ultherapy is FDA-cleared (510(k) K243035, 24 Feb 2025) to lift the eyebrow, lift lax submental (under-chin) and neck tissue, improve décolleté lines and wrinkles, and improve the appearance of skin laxity on the abdomen and the front and back of the arms — with a cleared purpose of "temporary changes" in the skin's appearance. Sofwave's clearance (K250146, 18 Apr 2025) lists treatment of acne scars, facial lines and wrinkles, brow lift, lifting lax submental and neck tissue in people 22 and older, short-term improvement in the appearance of cellulite, and skin laxity on the upper arms.

Morpheus8 is the one to read carefully.

Its 90 applicator holds a general 510(k) clearance (K240017, 13 Jun 2024) for dermatological procedures needing coagulation and contraction of soft tissue, or hemostasis — the wording does not list wrinkles, acne scars or fat, and at energies above 62 mJ/pin use is limited to skin types I-IV.

These are all cleared devices, not FDA-approved ones; "cleared" is the regulator's word for what a 510(k) does.

On timing, the AAD says that with one ultrasound treatment most people see modest lifting and tightening within 2 to 6 months; non-invasive radiofrequency is usually one treatment, with best results at about 6 months and results lasting 2 to 3 years with good skin care; and non-wounding lasers take 3 to 5 treatments, with results appearing 2 to 6 months after the last.

Its bottom line on the whole category: non-invasive tightening gives modest tightening and lifting, and a surgical lift such as a facelift gives the most dramatic results.

The full device-by-device comparison lives in our loose skin treatments guide.

Threads have the thinnest paper trail of the options here: our concerns research pass did not capture any FDA clearance text, longevity data or complication rates for thread lifts used on jowls, so we could not confirm them.

What the FDA's 510(k) database does show, from our fillers research: PDO threads (polydioxanone) sold for aesthetic use in the US are cleared as absorbable surgical sutures — for example PDO MAXX Threads (K190245, 2019) and Secret Line up / i-Thread (K240389, 2024) — only "for soft tissue approximation where use of absorbable sutures is appropriate", and several cleared indications expressly say the threads are not intended for lifting and supporting tissues and are for dermatological (skin) use only.

Marketing a PDO thread lift as an "FDA-cleared lift" goes beyond the clearance.

One product is the exception: Silhouette InstaLift, an absorbable poly(glycolide/L-lactide) suture — not PDO — is cleared (K200140, 2020) for mid-face suspension surgery to temporarily fixate the cheek sub-dermis in an elevated position.

The technique itself has a mainstream description: the American Society of Plastic Surgeons describes a thread lift — sometimes called a "lunchtime lift" — as absorbable, barbed sutures that tighten the face and neck by mechanically lifting tissue and stimulating collagen where the barbs sit, used for reducing wrinkles, early jowls and sagging skin.

That is a description of the procedure, not a regulatory status.

On results, a 2025 systematic review in Dermatologic Surgery (12 studies, 818 patients, mostly PDO) found improvement immediately after the procedure in all studies and mild complications, but follow-up reached at most 2 years, and the authors concluded long-term efficacy data are lacking.

Kybella (deoxycholic acid, a prescription drug) is FDA-approved only for moderate to severe fullness from submental — under-chin — fat in adults.

The label goes further for everything else: Kybella is not approved for fat outside the submental region, and the label says such use is not recommended.

Our fillers research spells out what that means for this page's question: jawline, jowl and other body uses are off-label.

The candidacy fine print matters for jowls specifically.

Before treating, the label tells providers to screen for other causes of under-chin fullness, such as an enlarged thyroid or swollen lymph nodes, and to weigh the risks in people with excess skin laxity or prominent platysmal bands, where results may not look good.

The treatment course on the label is up to 6 single treatments, at least 1 month apart.

In Kybella's pooled pivotal trials (513 treated people), swelling and edema occurred in 87% (against 43% of placebo subjects), bruising in 72%, pain in 70%, numbness in 66%, redness in 27% and hardness in 23%.

The AAD adds that some people are extremely swollen for as long as 2 weeks after chin-fat injections, though they can return to normal activities, and that full results show about 3 to 4 months after the last treatment.

What the treatment can and cannot reach, and what its sessions cost, is the kybella guide's territory.

Masseter Botox appears in jowl searches because the masseter — the chewing muscle at the back of the jaw — sits in the lower face.

What the labels say is unambiguous: botulinum toxin for the masseter is off-label for every US toxin, because no toxin label includes the masseter.

Botox Cosmetic's label is approved for temporary improvement of moderate to severe frown lines, crow's feet, forehead lines and (since October 2024) platysma bands — and it does not cover masseter slimming, the jawline, the double chin or jowls.

There is also no FDA-approved injectable or device indicated to treat a double chin with Botox, and toxin for the lower face and jaw, other than the platysma bands, is off-label.

On dosing we can only tell you what we did not find: no label, consensus paper or high-quality source in our research gives unit counts for jowl or "Nefertiti" toxin treatments — for these off-label areas, doses are set by the individual injector.

A provider who quotes you a specific number for a jowl toxin treatment is working from experience, not from a label.

Each option is priced on a different meter: fillers by the syringe, device treatments by the session, Kybella by the treatment — and with up to 6 treatments on the label, the sessions multiply.

The national figures that exist are surgeon fees, not med spa prices.

ASPS's filler cost page lists average costs of $715 for hyaluronic acid fillers and $901 for non-hyaluronic acid fillers such as Radiesse and Sculptra — average fees reported by ASPS member plastic surgeons, with no data year stated on the page.

For the fat-melting option, ASPS reports an average cost of $1,157 for nonsurgical fat reduction, a category that includes Kybella — again a member-surgeon fee, not a med spa price.

We did not find a national price figure for Ultherapy or Morpheus8 in our research, and we did not find a published price for thread lifts either.

Device makers point out that the number of sessions drives the total: Sofwave's maker describes its treatment as one 30- to 45-minute session.

Longevity runs on just as wide a range, and the figures come from different kinds of sources — a drug label, a society's table and a device clearance are not like-for-like.

Fillers: the AAD gives hyaluronic acid 4 to 12 months and poly-L-lactic acid 1 to 3 years; the FDA gives about 6 to 12 months for HA, about 18 months for calcium hydroxylapatite and up to 2 years for PLLA.

Devices: the AAD gives non-invasive radiofrequency results of 2 to 3 years with good skin care, while its ultrasound figure is an onset, not a duration — most people see modest lifting within 2 to 6 months of one treatment.

Kybella's anchored figure is an onset too: full results about 3 to 4 months after the last treatment.

For threads there is no reliable duration figure at all — the 2025 review's follow-up reached at most 2 years, and its authors concluded long-term efficacy data are lacking.

The treatment you choose decides the questions to ask.

Before booking any of the options above, ask three things: exactly which product or device the clinic uses, what that product's approval or that device's clearance actually covers, and who will perform the treatment under whose license.

Who may inject is state law: AmSpa, the medical spa trade association, describes botulinum toxin injections as the practice of medicine — a prescription drug is being used — so they must be done by a physician, an independent-practice nurse practitioner or another licensed professional acting within their scope, under rules that vary by state.

Two lookups cover the credentials you will hear claimed.

CertificationMatters.org, run by the American Board of Medical Specialties (ABMS), checks whether a doctor holds certification from an ABMS member board — and any claim of board certification should always name the specific board.

Nurse licenses (RN, APRN, LPN/VN) can be checked through Nursys, the national nurse licensure database, via its QuickConfirm search.

Our med spa checklist walks the full vetting process, start to finish.